Results 271 to 280 of about 119,989 (312)

Ammonia-induced lysosomal and mitochondrial damage: a novel perspective on T cell-based cancer immunotherapy. [PDF]

J Natl Cancer Cent
Shentu J, Xu H, Zhu F.
europepmc   +1 more source

Immunotherapy in Recurrent Ovarian Cancer. [PDF]

Biomedicines
Chen K, Wang J, Yang M, Deng S, Sun L.
europepmc   +1 more source

The CXCL1-CXCR2 Axis as a Component of Therapy Resistance, a Source of Side Effects in Cancer Treatment, and a Therapeutic Target. [PDF]

Cancers (Basel)
Korbecki J, Bosiacki M, Pilarczyk M, Kot M, Defort P, Walaszek I, Chlubek D, Baranowska-Bosiacka I.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Adoptive immunotherapy

Current Opinion in Oncology, 1997
Some of the most dramatic advances in the treatment of cancer have used the immune system in combination with conventional or transplantation chemotherapy. Adoptive immunotherapy has been used for relapses after allogeneic bone marrow transplantation, and it has been particularly effective for chronic myeloid leukemia.
K, Ballen, F M, Stewart
openaire   +2 more sources

Adoptive immunotherapy for cancer

Immunological Reviews, 2013
SummaryRecent clinical success has underscored the potential for immunotherapy based on the adoptive cell transfer (ACT) of engineered T lymphocytes to mediate dramatic, potent, and durable clinical responses. This success has led to the broader evaluation of engineered T‐lymphocyte‐based adoptive cell therapy to treat a broad range of malignancies. In
Marco Ruella, Michael Kalos
openaire   +2 more sources

Adoptive immunotherapy against sarcomas

Expert Opinion on Biological Therapy, 2014
Conventional treatments reached an unsatisfactory therapeutic plateau in the treatment of advanced unresectable bone and soft tissue sarcomas that remain an unsolved medical need. Several evidences support the concept that adoptive immunotherapy may effectively integrate within the complex and multidisciplinary treatment of sarcomas.In this work we ...
MESIANO, GIULIA, LEUCI, Valeria, GIRAUDO, LIDIA, Gammaitoni L, Carnevale Schianca F, Cangemi M, Rotolo R, CAPELLERO, Sonia, PIGNOCHINO, YMERA, Grignani G, AGLIETTA, Massimo, SANGIOLO, Dario   +11 more
openaire   +3 more sources

Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer

Cancer Treatment Reviews, 2001
The chemo-immunotherapy (CIT) and chemo-adoptive immunotherapy (CAIT) regimens tested in the past decade are summarized. From them we have learned a great deal about the interactions between various chemotherapeutic agents, immune modulating agents and effector cells.
R.B Hutchison, G.G Gomez, C.A Kruse
openaire   +2 more sources

Regulation of adoptive immunotherapy.

[Rinsho ketsueki] The Japanese journal of clinical hematology, 2016
Adoptive immunotherapy using chimeric antigen receptor (CAR)-modified T cells has provided a major breakthrough in the treatment of hematological malignancies. In Japan, it is expected that CD19 CAR-T cell therapy will be introduced earlier in clinical B cell malignancy settings and/or that a novel CAR-T cell therapy will be developed for non-B cell ...
Nobuhiro Nishio, Satoshi Suzuki, Yozo Nakazawa   +2 more
openaire   +3 more sources

Adoptive Immunotherapy for Malignant Glioma

The Cancer Journal, 2003
Despite remarkable advancements in imaging modalities and treatment options available to patients diagnosed with malignant brain tumors, the prognosis for those with high-grade lesions remains poor. The imprecise mechanisms of currently available treatments to manage these tumors do not spare damage to the normal surrounding brain and often result in ...
John H. Sampson, Peter E. Fecci, Duane Mitchell   +2 more
openaire   +3 more sources

Adoptive Immunotherapy in Chimeras [PDF]

, 2003
Depletion of T-cells from the marrow by treatment with absorbed antithymocyte globulin (ATG) prevents GVHD in DLA-identical littermates and transfusion of donor lymphocytes on days 1 and 2, 21 and 22 induces fatal GVHD. However transfusion on days 61 and 62 dose not produce GVHD and the animals survive.
Martin Weber, Kolb Hj, Wolfgang Guenther, Xiao Chen, Christoph Schmid, Michael Schleuning, A. Woiciechowski, Marie Roskrow, Georg Ledderose, O. Stoetzer   +9 more
openaire   +1 more source